FINI
Future challenges in management of recurrent/resistant Infection: development of antimicrobial Nanoparticulate systems and physical-chemical investigation of their Interactions with biofilm-associated infection (PNRR - Missione 4, Componente 2, Investimento 1.1 - Bando Prin 2022 - Decreto Direttoriale n. 104 del 02-02-2022)
WELCOME TO THE PRIN 2022 FINI PROJECT WEB SITE
(CUP J53D23008880006)
GOALS
Main goal of the FINI project is to design the correct therapeutic systems able to eradicate the biofilm-associated infections, so permitting a specific antimicrobial therapy without cytotoxicity and side effects.
Two main results:
- Develop nanotechnological platforms, with specific surface properties and sizes, addressed to reduce the formation of BPB in various models of human eukaryotic cells and explanted organs, to inhibit biofilm production and development and/or breaking/dissolving the mature biofilm.
- Clarify the mechanism of biofilm eradication, by an exhaustive physicochemical and morphological characterization of the biofilm produced by selected pathogen microorganisms.
The project involves two research units (RUs): University of Messina (RU1-UniME, Project Leader) and University of Catania (RU2-UniCT).
The project involves two research units (RUs): University of Messina (RU1-UniME, Project Leader) and University of Catania (RU2-UniCT).
Expected benefits and social
impact
The FINI project is in perfect agreement with some of the main objectives of the European Framework Program for Research and Innovation 2021-2027 (Horizon Europe), which has included health as the first cluster of the Global Challenges and European Industrial Competitiveness pillar. In particular, the development of innovative solutions and health technologies in order to improve and protect the health and wellbeing of citizens of all ages is among the goals of this cluster.
EXPECTED BENEFITS
For the manufacturers of antimicrobial products:
- A single step antimicrobial and anti-biofilm nano-functionalisation of the products
- Low-cost, sustainable and safe processes and products
- Novel in situ monitoring and quality control of therapy
- Low environmental footprint and prolonged lifecycle of the products
For the health care providers and patients
- Highly efficient antimicrobial and anti-biofilm products
- Novel efficient and safe nano-antimicrobials as an alternative to the obsolete antibiotics
- Reduce incidence and transmittance of bacterial infections
- Water and food safety
For Society
- Reduction of human loss
- Reduction of costs
- Resolution of contamination problems and improvement of human health quality life
- Possibility to guarantee food safety even to populations where water and food supply is more risky due to the presence of
biofilm-forming bacteria.
WORKING PACKAGEs (WPs)
WP1
ADMINISTRATION
WP4
CHARACTERIZATION OF BIOFILM TREATED BY NPS
WP2
PRODUCTION AND CHARACTERIZATION OF BIOFILM
WP5
IN VITRO/EX VIVO ASSAYS
WP3
DEVELOPMENT, PHYSICOCHEMICAL AND MORPHOLOGICAL CHARACTERIZATION OF ANTIMICROBIAL NANOPARTICLES (NPS)
WP6
DISSEMINATION